PILA PHARMA AB (DE:5KC)

FRANKFURT:5KC

5KC

PILA PHARMA AB

RESEARCH TOOLSreports

PILA PHARMA AB (5KC) Price & Analysis

0 Followers

5KC Stock Chart & Stats

€0.20

€0.09(20.09%)

At close: Jan 08 4:00 PM EST

€0.20

€0.09(20.09%)

Day’s Range― - ―

52-Week Range€0.09 - €0.41

Previous CloseN/A

Volume2.28K

Average Volume (3M)0.00

Market Cap

€7.40M

Enterprise Value€64.96M

Total Cash (Recent Filing)€1.08M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta0.02

Next Earnings

Aug 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding45,682,120

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio-0.37

Price to Book (P/B)4.82

Price to Sales (P/S)63.25

P/FCF Ratio-7.76

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / Clean Balance SheetMaintaining zero debt materially reduces refinancing and interest-rate vulnerability for a cash-burning biotech. Over 2–6 months this strengthens solvency and preserves strategic optionality for funding R&D or licensing without near-term fixed-interest obligations that could constrain development choices.

Materially Stronger Equity BaseA sizable equity increase provides an extended runway and reduces immediate dilution pressure versus smaller equity reserves. This stronger capital base improves the company’s ability to fund ongoing trials and development activities over the medium term, stabilising operations while seeking milestones or partnerships.

Focused Pipeline In Large Chronic MarketsA concentrated R&D focus on a TRPV1 antagonist for diabetes and obesity targets structurally large, chronic markets with persistent unmet needs. If clinical progression is successful, a single, scalable therapeutic can provide durable revenue potential and strategic licensing or partner opportunities in a high-demand therapeutic area.

Bears Say

Persistent Negative Cash GenerationConsistent negative operating and free cash flow indicates ongoing cash burn that will require external financing to sustain development. Over months this creates dilution risk, forces prioritisation of programs, and may limit bargaining power in deals or slow clinical progression if additional capital is delayed or expensive.

Widening Net LossesA materially larger annual net loss demonstrates increasing cash drain and limited operating leverage from current activities. Persistently expanding losses can erode equity cushions, increase refinancing needs, and heighten execution risk for development timelines if expense growth is not matched by funding or clinical inflection points.

Small, Volatile Revenue And Limited Operating LeverageModest and inconsistent revenue cannot cover fixed R&D and G&A costs, leaving the company reliant on capital markets or partners. The volatility undermines predictable cash flow and makes it difficult to demonstrate commercial traction or scale economics, keeping the firm in a capital-dependent development phase.

5KC FAQ

What was PILA PHARMA AB’s price range in the past 12 months?

PILA PHARMA AB lowest stock price was €0.09 and its highest was €0.41 in the past 12 months.

What is PILA PHARMA AB’s market cap?

PILA PHARMA AB’s market cap is €7.40M.

When is PILA PHARMA AB’s upcoming earnings report date?

PILA PHARMA AB’s upcoming earnings report date is Aug 20, 2026 which is in 141 days.

How were PILA PHARMA AB’s earnings last quarter?

PILA PHARMA AB released its earnings results on Feb 26, 2026. The company reported -€0.034 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.034.

Is PILA PHARMA AB overvalued?

According to Wall Street analysts PILA PHARMA AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does PILA PHARMA AB pay dividends?

PILA PHARMA AB does not currently pay dividends.

What is PILA PHARMA AB’s EPS estimate?

PILA PHARMA AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does PILA PHARMA AB have?

PILA PHARMA AB has 45,682,120 shares outstanding.

What happened to PILA PHARMA AB’s price movement after its last earnings report?

PILA PHARMA AB reported an EPS of -€0.034 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.869%.

Which hedge fund is a major shareholder of PILA PHARMA AB?

Currently, no hedge funds are holding shares in DE:5KC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

PILA PHARMA AB

PILA PHARMA AB (publ) operates as a clinical stage pharmaceutical company in Sweden. It is developing XEN-D0501, a TRPV1 antagonist that has completed two phase 2a clinical trials for type 2 diabetes. PILA PHARMA AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.